All In Biotech

Free tool

FAERS Monitor: Scenesse

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210797 or its brand name (Scenesse, Afamelanotide). Reports on generic versions are filed under their own applications.

Reports

21

Serious

17

81% of reports

Hospitalization

9

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anaphylactic reaction4
  • contraindication to medical treatment3
  • type i hypersensitivity3
  • implant site hypersensitivity2
  • implant site pruritus2
  • implant site urticaria2
  • malignant melanoma2
  • vomiting2
  • acute kidney injury1
  • acute on chronic liver failure1
  • appendicitis1
  • ascites1
  • asthenia1
  • cellulitis1
  • death1

Reports by year received

View as table
YearReports
20201
20212
20224
20232
20244
20255
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
implant site urticaria220887.05505.523,016
implant site hypersensitivity218395.94857.620,320
acute on chronic liver failure14663.2685.41,159
implant site pruritus22232.9596.52,504
contraindication to medical treatmentSignal31971.0690.54,093
type i hypersensitivitySignal3854.5299.61,774
malignant melanoma2149.640.0165
appendicitis1107.215.826
anaphylactic reactionSignal472.530.0216
ascites134.15.08
cellulitis119.92.94
acute kidney injury16.51.01
vomiting24.31.12
asthenia12.70.40
death11.20.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.